Basilea Pharmaceutica Management
Management criteria checks 3/4
Basilea Pharmaceutica's CEO is David Veitch, appointed in Apr 2018, has a tenure of 6.58 years. total yearly compensation is CHF1.75M, comprised of 35% salary and 65% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth CHF53.71K. The average tenure of the management team and the board of directors is 6.8 years and 9.6 years respectively.
Key information
David Veitch
Chief executive officer
CHF 1.7m
Total compensation
CEO salary percentage | 35.0% |
CEO tenure | 6.6yrs |
CEO ownership | 0.01% |
Management average tenure | 6.8yrs |
Board average tenure | 9.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -CHF 652k |
Mar 31 2024 | n/a | n/a | CHF 5m |
Dec 31 2023 | CHF 2m | CHF 611k | CHF 10m |
Sep 30 2023 | n/a | n/a | CHF 33m |
Jun 30 2023 | n/a | n/a | CHF 56m |
Mar 31 2023 | n/a | n/a | CHF 34m |
Dec 31 2022 | CHF 2m | CHF 599k | CHF 12m |
Sep 30 2022 | n/a | n/a | CHF 6m |
Jun 30 2022 | n/a | n/a | CHF 851k |
Mar 31 2022 | n/a | n/a | -CHF 3m |
Dec 31 2021 | CHF 2m | CHF 594k | -CHF 7m |
Sep 30 2021 | n/a | n/a | -CHF 26m |
Jun 30 2021 | n/a | n/a | -CHF 45m |
Mar 31 2021 | n/a | n/a | -CHF 30m |
Dec 31 2020 | CHF 1m | CHF 589k | -CHF 15m |
Sep 30 2020 | n/a | n/a | -CHF 6m |
Jun 30 2020 | n/a | n/a | CHF 3m |
Mar 31 2020 | n/a | n/a | -CHF 10m |
Dec 31 2019 | CHF 1m | CHF 583k | -CHF 22m |
Sep 30 2019 | n/a | n/a | -CHF 23m |
Jun 30 2019 | n/a | n/a | -CHF 24m |
Mar 31 2019 | n/a | n/a | -CHF 28m |
Dec 31 2018 | CHF 2m | CHF 529k | -CHF 31m |
Compensation vs Market: David's total compensation ($USD1.95M) is above average for companies of similar size in the UK market ($USD988.12K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Veitch (59 yo)
6.6yrs
Tenure
CHF 1,745,679
Compensation
Mr. David Veitch has been the Chief Executive Officer of Basilea Pharmaceutica Ltd. since April 19, 2018 and Basilea Pharmaceutica International Ltd., since September 1, 2014. Mr. Veitch joined Basilea in...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 6.6yrs | CHF 1.75m | 0.011% CHF 53.7k | |
Chief Financial Officer | 5.6yrs | no data | 0.0041% CHF 20.7k | |
Chief Technology Officer | 6.5yrs | no data | no data | |
Chief Scientific Officer | 15.8yrs | no data | 0.0041% CHF 20.7k | |
Chief Medical Officer | 6.8yrs | no data | no data | |
Head of Corporate Communications & Investor Relations | no data | no data | no data | |
General Counsel & Corporate Secretary | 7.3yrs | no data | no data | |
Head of Corporate Development | no data | no data | no data | |
Head of Global Human Resources | 7.8yrs | no data | no data | |
Head of Global Affairs | 6.8yrs | no data | no data | |
Head of Global Quality Management | 2.2yrs | no data | no data | |
Head of Biology | no data | no data | no data |
6.8yrs
Average Tenure
58yo
Average Age
Experienced Management: BSLNz's management team is seasoned and experienced (6.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Non-Executive Director | 7.6yrs | CHF 192.13k | 0.0061% CHF 30.4k | |
Independent Non-Executive Director | 2.6yrs | CHF 186.88k | no data | |
Independent Chairman of the Board | 13yrs | CHF 337.68k | 0.0049% CHF 24.4k | |
Independent Non-Executive Director | 11.6yrs | CHF 211.75k | 0.015% CHF 72.6k | |
Independent Non-Executive Director | 1.6yrs | CHF 192.13k | no data | |
Independent Vice-Chairman | 13yrs | CHF 224.80k | 0.0098% CHF 49.2k |
9.6yrs
Average Tenure
67yo
Average Age
Experienced Board: BSLNz's board of directors are considered experienced (9.6 years average tenure).